Rituximab

Patients with pemphigus in complete remission had a reduced risk of relapse after receiving an additional rituximab infusion at month 6, according to a study.

Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward developing “new and improved” B-cell depleting agents for patients with the disease, according to researchers.

The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma.

SAN DIEGO — Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind trial presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Paolo Caimi, MD, spoke with Healio about the latest results from the POLARIX trial presented at ASH Annual Meeting and Exposition.

WASHINGTON — In this video, Ambreesh Chawla, MD, summarizes salient and practice-changing presentations in rheumatoid arthritis from ACR Convergence 2024.

Clinical trial results in Sjögren’s disease over the last decade have volleyed between encouraging successes and deflating failures, but with several new drugs advancing through the pipeline, hopes are high yet again.

In this video, John H. Stone, MD, MPH, professor of medicine at Harvard Medical School, the Edward A. Fox Chair in Medicine at Massachusetts General Hospital, discusses an important facet of IgG4-related disease other rheumatologists and providers should be aware of.

WASHINGTON — In this video, Jeffrey A. Sparks, MD, MMSc, highlights an observational study investigating the impact of disease-modifying antirheumatic drugs on rheumatoid arthritis-associated interstitial lung disease.

WASHINGTON — In this video, Jeffrey A. Sparks, MD, MMSc, discusses two translational studies focused on human tissue for the treatment of rheumatoid arthritis.